狭心症治療薬のグローバル市場インサイト・予測（～2028年）

• 英文タイトル：Global Antianginal Agents Market Insights, Forecast to 2028

• レポートコード：QY2207E10355 • 出版社/出版日：QYResearch / 2022年7月 • レポート形態：英文、PDF、128ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥725,200 (USD4,900)	▷ お問い合わせ
Multi User	￥1,087,800 (USD7,350)	▷ お問い合わせ
Enterprise License	￥1,450,400 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

新型コロナウイルス感染症のパンデミックにより、世界の狭心症治療薬の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に狭心症治療薬の世界市場のxxx％を占める「硝酸塩」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院薬局」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国の狭心症治療薬の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの狭心症治療薬市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの狭心症治療薬市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 狭心症治療薬のグローバル主要メーカーには、Teva、Merck、Pfizer、Mylan N.V.、Elite Pharmaceutical Solution Inc.、Pharmaoffer.com、AstraZeneca、ACETO、Nesher Pharmaceuticals、Taj pharmaceutical、Espero BioPharma、Hikma Pharmaceuticals、Athenex、Aurobindo Pharma、AMRI、Intas Pharmaceuticals、Glenmark Pharmaceuticals、Troikaa、Square Pharmaceuticals、Sun Pharmaceutical、Unique Pharmaceuticals、Ipca Laboratories、Sandoz、Globus Remedies、Shandong Fangming Pharmaceutical Group、ReYoung Pharmaceuticalなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 狭心症治療薬市場は、種類と用途によって区分されます。世界の狭心症治療薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 硝酸塩、β遮断薬、カルシウム拮抗薬 【用途別セグメント】 病院薬局、小売店薬局、オンライン薬局 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 狭心症治療薬製品概要 - 種類別市場（硝酸塩、β遮断薬、カルシウム拮抗薬） - 用途別市場（病院薬局、小売店薬局、オンライン薬局） - 調査の目的 ・エグゼクティブサマリー - 世界の狭心症治療薬販売量予測2017-2028 - 世界の狭心症治療薬売上予測2017-2028 - 狭心症治療薬の地域別販売量 - 狭心症治療薬の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別狭心症治療薬販売量 - 主要メーカー別狭心症治療薬売上 - 主要メーカー別狭心症治療薬価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（硝酸塩、β遮断薬、カルシウム拮抗薬） - 狭心症治療薬の種類別販売量 - 狭心症治療薬の種類別売上 - 狭心症治療薬の種類別価格 ・用途別市場規模（病院薬局、小売店薬局、オンライン薬局） - 狭心症治療薬の用途別販売量 - 狭心症治療薬の用途別売上 - 狭心症治療薬の用途別価格 ・北米市場 - 北米の狭心症治療薬市場規模（種類別、用途別） - 主要国別の狭心症治療薬市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの狭心症治療薬市場規模（種類別、用途別） - 主要国別の狭心症治療薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の狭心症治療薬市場規模（種類別、用途別） - 主要国別の狭心症治療薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の狭心症治療薬市場規模（種類別、用途別） - 主要国別の狭心症治療薬市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの狭心症治療薬市場規模（種類別、用途別） - 主要国別の狭心症治療薬市場規模（トルコ、サウジアラビア） ・企業情報 Teva、Merck、Pfizer、Mylan N.V.、Elite Pharmaceutical Solution Inc.、Pharmaoffer.com、AstraZeneca、ACETO、Nesher Pharmaceuticals、Taj pharmaceutical、Espero BioPharma、Hikma Pharmaceuticals、Athenex、Aurobindo Pharma、AMRI、Intas Pharmaceuticals、Glenmark Pharmaceuticals、Troikaa、Square Pharmaceuticals、Sun Pharmaceutical、Unique Pharmaceuticals、Ipca Laboratories、Sandoz、Globus Remedies、Shandong Fangming Pharmaceutical Group、ReYoung Pharmaceutical ・産業チェーン及び販売チャネル分析 - 狭心症治療薬の産業チェーン分析 - 狭心症治療薬の原材料 - 狭心症治療薬の生産プロセス - 狭心症治療薬の販売及びマーケティング - 狭心症治療薬の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 狭心症治療薬の産業動向 - 狭心症治療薬のマーケットドライバー - 狭心症治療薬の課題 - 狭心症治療薬の阻害要因 ・主な調査結果

Antianginal agents is a term used to describe a wide variety of medicines that are used in the management of angina.
Market Analysis and Insights: Global Antianginal Agents Market
Due to the COVID-19 pandemic, the global Antianginal Agents market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Nitrates accounting for % of the Antianginal Agents global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital Pharmacies segment is altered to an % CAGR throughout this forecast period.
China Antianginal Agents market size is valued at US$ million in 2021, while the US and Europe Antianginal Agents are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Antianginal Agents landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Antianginal Agents include Teva, Merck, Pfizer, Mylan N.V., Elite Pharmaceutical Solution Inc., Pharmaoffer.com, AstraZeneca, ACETO and Nesher Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Antianginal Agents Scope and Segment
Antianginal Agents market is segmented by Type and by Distribution Channel. Players, stakeholders, and other participants in the global Antianginal Agents market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Distribution Channel for the period 2017-2028.
Segment by Type
Nitrates
Beta Blockers
Calcium Channel Blockers
Segment by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Company
Teva
Merck
Pfizer
Mylan N.V.
Elite Pharmaceutical Solution Inc.
Pharmaoffer.com
AstraZeneca
ACETO
Nesher Pharmaceuticals
Taj pharmaceutical
Espero BioPharma
Hikma Pharmaceuticals
Athenex
Aurobindo Pharma
AMRI
Intas Pharmaceuticals
Glenmark Pharmaceuticals
Troikaa
Square Pharmaceuticals
Sun Pharmaceutical
Unique Pharmaceuticals
Ipca Laboratories
Sandoz
Globus Remedies
Shandong Fangming Pharmaceutical Group
ReYoung Pharmaceutical
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

レポート目次

---

1 Study Coverage
1.1 Antianginal Agents Product Introduction
1.2 Market by Type
1.2.1 Global Antianginal Agents Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Nitrates
1.2.3 Beta Blockers
1.2.4 Calcium Channel Blockers
1.3 Market by Distribution Channel
1.3.1 Global Antianginal Agents Market Size Growth Rate by Distribution Channel, 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Antianginal Agents Sales Estimates and Forecasts 2017-2028
2.2 Global Antianginal Agents Revenue Estimates and Forecasts 2017-2028
2.3 Global Antianginal Agents Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Antianginal Agents Sales by Region
2.4.1 Global Antianginal Agents Sales by Region (2017-2022)
2.4.2 Global Sales Antianginal Agents by Region (2023-2028)
2.5 Global Antianginal Agents Revenue by Region
2.5.1 Global Antianginal Agents Revenue by Region (2017-2022)
2.5.2 Global Antianginal Agents Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Antianginal Agents Sales by Manufacturers
3.1.1 Global Top Antianginal Agents Manufacturers by Sales (2017-2022)
3.1.2 Global Antianginal Agents Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Antianginal Agents in 2021
3.2 Global Antianginal Agents Revenue by Manufacturers
3.2.1 Global Antianginal Agents Revenue by Manufacturers (2017-2022)
3.2.2 Global Antianginal Agents Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Antianginal Agents Revenue in 2021
3.3 Global Antianginal Agents Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Antianginal Agents Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Antianginal Agents Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Antianginal Agents Sales by Type
4.1.1 Global Antianginal Agents Historical Sales by Type (2017-2022)
4.1.2 Global Antianginal Agents Forecasted Sales by Type (2023-2028)
4.1.3 Global Antianginal Agents Sales Market Share by Type (2017-2028)
4.2 Global Antianginal Agents Revenue by Type
4.2.1 Global Antianginal Agents Historical Revenue by Type (2017-2022)
4.2.2 Global Antianginal Agents Forecasted Revenue by Type (2023-2028)
4.2.3 Global Antianginal Agents Revenue Market Share by Type (2017-2028)
4.3 Global Antianginal Agents Price by Type
4.3.1 Global Antianginal Agents Price by Type (2017-2022)
4.3.2 Global Antianginal Agents Price Forecast by Type (2023-2028)
5 Market Size by Distribution Channel
5.1 Global Antianginal Agents Sales by Distribution Channel
5.1.1 Global Antianginal Agents Historical Sales by Distribution Channel (2017-2022)
5.1.2 Global Antianginal Agents Forecasted Sales by Distribution Channel (2023-2028)
5.1.3 Global Antianginal Agents Sales Market Share by Distribution Channel (2017-2028)
5.2 Global Antianginal Agents Revenue by Distribution Channel
5.2.1 Global Antianginal Agents Historical Revenue by Distribution Channel (2017-2022)
5.2.2 Global Antianginal Agents Forecasted Revenue by Distribution Channel (2023-2028)
5.2.3 Global Antianginal Agents Revenue Market Share by Distribution Channel (2017-2028)
5.3 Global Antianginal Agents Price by Distribution Channel
5.3.1 Global Antianginal Agents Price by Distribution Channel (2017-2022)
5.3.2 Global Antianginal Agents Price Forecast by Distribution Channel (2023-2028)
6 North America
6.1 North America Antianginal Agents Market Size by Type
6.1.1 North America Antianginal Agents Sales by Type (2017-2028)
6.1.2 North America Antianginal Agents Revenue by Type (2017-2028)
6.2 North America Antianginal Agents Market Size by Distribution Channel
6.2.1 North America Antianginal Agents Sales by Distribution Channel (2017-2028)
6.2.2 North America Antianginal Agents Revenue by Distribution Channel (2017-2028)
6.3 North America Antianginal Agents Market Size by Country
6.3.1 North America Antianginal Agents Sales by Country (2017-2028)
6.3.2 North America Antianginal Agents Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Antianginal Agents Market Size by Type
7.1.1 Europe Antianginal Agents Sales by Type (2017-2028)
7.1.2 Europe Antianginal Agents Revenue by Type (2017-2028)
7.2 Europe Antianginal Agents Market Size by Distribution Channel
7.2.1 Europe Antianginal Agents Sales by Distribution Channel (2017-2028)
7.2.2 Europe Antianginal Agents Revenue by Distribution Channel (2017-2028)
7.3 Europe Antianginal Agents Market Size by Country
7.3.1 Europe Antianginal Agents Sales by Country (2017-2028)
7.3.2 Europe Antianginal Agents Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Antianginal Agents Market Size by Type
8.1.1 Asia Pacific Antianginal Agents Sales by Type (2017-2028)
8.1.2 Asia Pacific Antianginal Agents Revenue by Type (2017-2028)
8.2 Asia Pacific Antianginal Agents Market Size by Distribution Channel
8.2.1 Asia Pacific Antianginal Agents Sales by Distribution Channel (2017-2028)
8.2.2 Asia Pacific Antianginal Agents Revenue by Distribution Channel (2017-2028)
8.3 Asia Pacific Antianginal Agents Market Size by Region
8.3.1 Asia Pacific Antianginal Agents Sales by Region (2017-2028)
8.3.2 Asia Pacific Antianginal Agents Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Antianginal Agents Market Size by Type
9.1.1 Latin America Antianginal Agents Sales by Type (2017-2028)
9.1.2 Latin America Antianginal Agents Revenue by Type (2017-2028)
9.2 Latin America Antianginal Agents Market Size by Distribution Channel
9.2.1 Latin America Antianginal Agents Sales by Distribution Channel (2017-2028)
9.2.2 Latin America Antianginal Agents Revenue by Distribution Channel (2017-2028)
9.3 Latin America Antianginal Agents Market Size by Country
9.3.1 Latin America Antianginal Agents Sales by Country (2017-2028)
9.3.2 Latin America Antianginal Agents Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Antianginal Agents Market Size by Type
10.1.1 Middle East and Africa Antianginal Agents Sales by Type (2017-2028)
10.1.2 Middle East and Africa Antianginal Agents Revenue by Type (2017-2028)
10.2 Middle East and Africa Antianginal Agents Market Size by Distribution Channel
10.2.1 Middle East and Africa Antianginal Agents Sales by Distribution Channel (2017-2028)
10.2.2 Middle East and Africa Antianginal Agents Revenue by Distribution Channel (2017-2028)
10.3 Middle East and Africa Antianginal Agents Market Size by Country
10.3.1 Middle East and Africa Antianginal Agents Sales by Country (2017-2028)
10.3.2 Middle East and Africa Antianginal Agents Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Teva
11.1.1 Teva Corporation Information
11.1.2 Teva Overview
11.1.3 Teva Antianginal Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Teva Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Teva Recent Developments
11.2 Merck
11.2.1 Merck Corporation Information
11.2.2 Merck Overview
11.2.3 Merck Antianginal Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Merck Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Merck Recent Developments
11.3 Pfizer
11.3.1 Pfizer Corporation Information
11.3.2 Pfizer Overview
11.3.3 Pfizer Antianginal Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Pfizer Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Pfizer Recent Developments
11.4 Mylan N.V.
11.4.1 Mylan N.V. Corporation Information
11.4.2 Mylan N.V. Overview
11.4.3 Mylan N.V. Antianginal Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Mylan N.V. Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Mylan N.V. Recent Developments
11.5 Elite Pharmaceutical Solution Inc.
11.5.1 Elite Pharmaceutical Solution Inc. Corporation Information
11.5.2 Elite Pharmaceutical Solution Inc. Overview
11.5.3 Elite Pharmaceutical Solution Inc. Antianginal Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Elite Pharmaceutical Solution Inc. Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Elite Pharmaceutical Solution Inc. Recent Developments
11.6 Pharmaoffer.com
11.6.1 Pharmaoffer.com Corporation Information
11.6.2 Pharmaoffer.com Overview
11.6.3 Pharmaoffer.com Antianginal Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Pharmaoffer.com Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Pharmaoffer.com Recent Developments
11.7 AstraZeneca
11.7.1 AstraZeneca Corporation Information
11.7.2 AstraZeneca Overview
11.7.3 AstraZeneca Antianginal Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 AstraZeneca Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 AstraZeneca Recent Developments
11.8 ACETO
11.8.1 ACETO Corporation Information
11.8.2 ACETO Overview
11.8.3 ACETO Antianginal Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 ACETO Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 ACETO Recent Developments
11.9 Nesher Pharmaceuticals
11.9.1 Nesher Pharmaceuticals Corporation Information
11.9.2 Nesher Pharmaceuticals Overview
11.9.3 Nesher Pharmaceuticals Antianginal Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Nesher Pharmaceuticals Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Nesher Pharmaceuticals Recent Developments
11.10 Taj pharmaceutical
11.10.1 Taj pharmaceutical Corporation Information
11.10.2 Taj pharmaceutical Overview
11.10.3 Taj pharmaceutical Antianginal Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Taj pharmaceutical Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Taj pharmaceutical Recent Developments
11.11 Espero BioPharma
11.11.1 Espero BioPharma Corporation Information
11.11.2 Espero BioPharma Overview
11.11.3 Espero BioPharma Antianginal Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Espero BioPharma Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Espero BioPharma Recent Developments
11.12 Hikma Pharmaceuticals
11.12.1 Hikma Pharmaceuticals Corporation Information
11.12.2 Hikma Pharmaceuticals Overview
11.12.3 Hikma Pharmaceuticals Antianginal Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Hikma Pharmaceuticals Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Hikma Pharmaceuticals Recent Developments
11.13 Athenex
11.13.1 Athenex Corporation Information
11.13.2 Athenex Overview
11.13.3 Athenex Antianginal Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Athenex Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Athenex Recent Developments
11.14 Aurobindo Pharma
11.14.1 Aurobindo Pharma Corporation Information
11.14.2 Aurobindo Pharma Overview
11.14.3 Aurobindo Pharma Antianginal Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Aurobindo Pharma Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Aurobindo Pharma Recent Developments
11.15 AMRI
11.15.1 AMRI Corporation Information
11.15.2 AMRI Overview
11.15.3 AMRI Antianginal Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 AMRI Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 AMRI Recent Developments
11.16 Intas Pharmaceuticals
11.16.1 Intas Pharmaceuticals Corporation Information
11.16.2 Intas Pharmaceuticals Overview
11.16.3 Intas Pharmaceuticals Antianginal Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Intas Pharmaceuticals Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Intas Pharmaceuticals Recent Developments
11.17 Glenmark Pharmaceuticals
11.17.1 Glenmark Pharmaceuticals Corporation Information
11.17.2 Glenmark Pharmaceuticals Overview
11.17.3 Glenmark Pharmaceuticals Antianginal Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 Glenmark Pharmaceuticals Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Glenmark Pharmaceuticals Recent Developments
11.18 Troikaa
11.18.1 Troikaa Corporation Information
11.18.2 Troikaa Overview
11.18.3 Troikaa Antianginal Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.18.4 Troikaa Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 Troikaa Recent Developments
11.19 Square Pharmaceuticals
11.19.1 Square Pharmaceuticals Corporation Information
11.19.2 Square Pharmaceuticals Overview
11.19.3 Square Pharmaceuticals Antianginal Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.19.4 Square Pharmaceuticals Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.19.5 Square Pharmaceuticals Recent Developments
11.20 Sun Pharmaceutical
11.20.1 Sun Pharmaceutical Corporation Information
11.20.2 Sun Pharmaceutical Overview
11.20.3 Sun Pharmaceutical Antianginal Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.20.4 Sun Pharmaceutical Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.20.5 Sun Pharmaceutical Recent Developments
11.21 Unique Pharmaceuticals
11.21.1 Unique Pharmaceuticals Corporation Information
11.21.2 Unique Pharmaceuticals Overview
11.21.3 Unique Pharmaceuticals Antianginal Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.21.4 Unique Pharmaceuticals Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.21.5 Unique Pharmaceuticals Recent Developments
11.22 Ipca Laboratories
11.22.1 Ipca Laboratories Corporation Information
11.22.2 Ipca Laboratories Overview
11.22.3 Ipca Laboratories Antianginal Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.22.4 Ipca Laboratories Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.22.5 Ipca Laboratories Recent Developments
11.23 Sandoz
11.23.1 Sandoz Corporation Information
11.23.2 Sandoz Overview
11.23.3 Sandoz Antianginal Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.23.4 Sandoz Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.23.5 Sandoz Recent Developments
11.24 Globus Remedies
11.24.1 Globus Remedies Corporation Information
11.24.2 Globus Remedies Overview
11.24.3 Globus Remedies Antianginal Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.24.4 Globus Remedies Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.24.5 Globus Remedies Recent Developments
11.25 Shandong Fangming Pharmaceutical Group
11.25.1 Shandong Fangming Pharmaceutical Group Corporation Information
11.25.2 Shandong Fangming Pharmaceutical Group Overview
11.25.3 Shandong Fangming Pharmaceutical Group Antianginal Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.25.4 Shandong Fangming Pharmaceutical Group Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.25.5 Shandong Fangming Pharmaceutical Group Recent Developments
11.26 ReYoung Pharmaceutical
11.26.1 ReYoung Pharmaceutical Corporation Information
11.26.2 ReYoung Pharmaceutical Overview
11.26.3 ReYoung Pharmaceutical Antianginal Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.26.4 ReYoung Pharmaceutical Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.26.5 ReYoung Pharmaceutical Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Antianginal Agents Industry Chain Analysis
12.2 Antianginal Agents Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Antianginal Agents Production Mode & Process
12.4 Antianginal Agents Sales and Marketing
12.4.1 Antianginal Agents Sales Channels
12.4.2 Antianginal Agents Distributors
12.5 Antianginal Agents Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Antianginal Agents Industry Trends
13.2 Antianginal Agents Market Drivers
13.3 Antianginal Agents Market Challenges
13.4 Antianginal Agents Market Restraints
14 Key Findings in The Global Antianginal Agents Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Antianginal Agents Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Nitrates
Table 3. Major Manufacturers of Beta Blockers
Table 4. Major Manufacturers of Calcium Channel Blockers
Table 5. Global Antianginal Agents Market Size Growth Rate by Distribution Channel, 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Antianginal Agents Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global Antianginal Agents Sales by Region (2017-2022) & (K Units)
Table 8. Global Antianginal Agents Sales Market Share by Region (2017-2022)
Table 9. Global Antianginal Agents Sales by Region (2023-2028) & (K Units)
Table 10. Global Antianginal Agents Sales Market Share by Region (2023-2028)
Table 11. Global Antianginal Agents Revenue by Region (2017-2022) & (US$ Million)
Table 12. Global Antianginal Agents Revenue Market Share by Region (2017-2022)
Table 13. Global Antianginal Agents Revenue by Region (2023-2028) & (US$ Million)
Table 14. Global Antianginal Agents Revenue Market Share by Region (2023-2028)
Table 15. Global Antianginal Agents Sales by Manufacturers (2017-2022) & (K Units)
Table 16. Global Antianginal Agents Sales Share by Manufacturers (2017-2022)
Table 17. Global Antianginal Agents Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 18. Global Antianginal Agents Revenue Share by Manufacturers (2017-2022)
Table 19. Antianginal Agents Price by Manufacturers (2017-2022) &(US$/Unit)
Table 20. Global Antianginal Agents Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 21. Global Antianginal Agents by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antianginal Agents as of 2021)
Table 22. Antianginal Agents Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Antianginal Agents Product Offered
Table 24. Date of Manufacturers Enter into Antianginal Agents Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Antianginal Agents Sales by Type (2017-2022) & (K Units)
Table 27. Global Antianginal Agents Sales by Type (2023-2028) & (K Units)
Table 28. Global Antianginal Agents Sales Share by Type (2017-2022)
Table 29. Global Antianginal Agents Sales Share by Type (2023-2028)
Table 30. Global Antianginal Agents Revenue by Type (2017-2022) & (US$ Million)
Table 31. Global Antianginal Agents Revenue by Type (2023-2028) & (US$ Million)
Table 32. Global Antianginal Agents Revenue Share by Type (2017-2022)
Table 33. Global Antianginal Agents Revenue Share by Type (2023-2028)
Table 34. Antianginal Agents Price by Type (2017-2022) & (US$/Unit)
Table 35. Global Antianginal Agents Price Forecast by Type (2023-2028) & (US$/Unit)
Table 36. Global Antianginal Agents Sales by Distribution Channel (2017-2022) & (K Units)
Table 37. Global Antianginal Agents Sales by Distribution Channel (2023-2028) & (K Units)
Table 38. Global Antianginal Agents Sales Share by Distribution Channel (2017-2022)
Table 39. Global Antianginal Agents Sales Share by Distribution Channel (2023-2028)
Table 40. Global Antianginal Agents Revenue by Distribution Channel (2017-2022) & (US$ Million)
Table 41. Global Antianginal Agents Revenue by Distribution Channel (2023-2028) & (US$ Million)
Table 42. Global Antianginal Agents Revenue Share by Distribution Channel (2017-2022)
Table 43. Global Antianginal Agents Revenue Share by Distribution Channel (2023-2028)
Table 44. Antianginal Agents Price by Distribution Channel (2017-2022) & (US$/Unit)
Table 45. Global Antianginal Agents Price Forecast by Distribution Channel (2023-2028) & (US$/Unit)
Table 46. North America Antianginal Agents Sales by Type (2017-2022) & (K Units)
Table 47. North America Antianginal Agents Sales by Type (2023-2028) & (K Units)
Table 48. North America Antianginal Agents Revenue by Type (2017-2022) & (US$ Million)
Table 49. North America Antianginal Agents Revenue by Type (2023-2028) & (US$ Million)
Table 50. North America Antianginal Agents Sales by Distribution Channel (2017-2022) & (K Units)
Table 51. North America Antianginal Agents Sales by Distribution Channel (2023-2028) & (K Units)
Table 52. North America Antianginal Agents Revenue by Distribution Channel (2017-2022) & (US$ Million)
Table 53. North America Antianginal Agents Revenue by Distribution Channel (2023-2028) & (US$ Million)
Table 54. North America Antianginal Agents Sales by Country (2017-2022) & (K Units)
Table 55. North America Antianginal Agents Sales by Country (2023-2028) & (K Units)
Table 56. North America Antianginal Agents Revenue by Country (2017-2022) & (US$ Million)
Table 57. North America Antianginal Agents Revenue by Country (2023-2028) & (US$ Million)
Table 58. Europe Antianginal Agents Sales by Type (2017-2022) & (K Units)
Table 59. Europe Antianginal Agents Sales by Type (2023-2028) & (K Units)
Table 60. Europe Antianginal Agents Revenue by Type (2017-2022) & (US$ Million)
Table 61. Europe Antianginal Agents Revenue by Type (2023-2028) & (US$ Million)
Table 62. Europe Antianginal Agents Sales by Distribution Channel (2017-2022) & (K Units)
Table 63. Europe Antianginal Agents Sales by Distribution Channel (2023-2028) & (K Units)
Table 64. Europe Antianginal Agents Revenue by Distribution Channel (2017-2022) & (US$ Million)
Table 65. Europe Antianginal Agents Revenue by Distribution Channel (2023-2028) & (US$ Million)
Table 66. Europe Antianginal Agents Sales by Country (2017-2022) & (K Units)
Table 67. Europe Antianginal Agents Sales by Country (2023-2028) & (K Units)
Table 68. Europe Antianginal Agents Revenue by Country (2017-2022) & (US$ Million)
Table 69. Europe Antianginal Agents Revenue by Country (2023-2028) & (US$ Million)
Table 70. Asia Pacific Antianginal Agents Sales by Type (2017-2022) & (K Units)
Table 71. Asia Pacific Antianginal Agents Sales by Type (2023-2028) & (K Units)
Table 72. Asia Pacific Antianginal Agents Revenue by Type (2017-2022) & (US$ Million)
Table 73. Asia Pacific Antianginal Agents Revenue by Type (2023-2028) & (US$ Million)
Table 74. Asia Pacific Antianginal Agents Sales by Distribution Channel (2017-2022) & (K Units)
Table 75. Asia Pacific Antianginal Agents Sales by Distribution Channel (2023-2028) & (K Units)
Table 76. Asia Pacific Antianginal Agents Revenue by Distribution Channel (2017-2022) & (US$ Million)
Table 77. Asia Pacific Antianginal Agents Revenue by Distribution Channel (2023-2028) & (US$ Million)
Table 78. Asia Pacific Antianginal Agents Sales by Region (2017-2022) & (K Units)
Table 79. Asia Pacific Antianginal Agents Sales by Region (2023-2028) & (K Units)
Table 80. Asia Pacific Antianginal Agents Revenue by Region (2017-2022) & (US$ Million)
Table 81. Asia Pacific Antianginal Agents Revenue by Region (2023-2028) & (US$ Million)
Table 82. Latin America Antianginal Agents Sales by Type (2017-2022) & (K Units)
Table 83. Latin America Antianginal Agents Sales by Type (2023-2028) & (K Units)
Table 84. Latin America Antianginal Agents Revenue by Type (2017-2022) & (US$ Million)
Table 85. Latin America Antianginal Agents Revenue by Type (2023-2028) & (US$ Million)
Table 86. Latin America Antianginal Agents Sales by Distribution Channel (2017-2022) & (K Units)
Table 87. Latin America Antianginal Agents Sales by Distribution Channel (2023-2028) & (K Units)
Table 88. Latin America Antianginal Agents Revenue by Distribution Channel (2017-2022) & (US$ Million)
Table 89. Latin America Antianginal Agents Revenue by Distribution Channel (2023-2028) & (US$ Million)
Table 90. Latin America Antianginal Agents Sales by Country (2017-2022) & (K Units)
Table 91. Latin America Antianginal Agents Sales by Country (2023-2028) & (K Units)
Table 92. Latin America Antianginal Agents Revenue by Country (2017-2022) & (US$ Million)
Table 93. Latin America Antianginal Agents Revenue by Country (2023-2028) & (US$ Million)
Table 94. Middle East and Africa Antianginal Agents Sales by Type (2017-2022) & (K Units)
Table 95. Middle East and Africa Antianginal Agents Sales by Type (2023-2028) & (K Units)
Table 96. Middle East and Africa Antianginal Agents Revenue by Type (2017-2022) & (US$ Million)
Table 97. Middle East and Africa Antianginal Agents Revenue by Type (2023-2028) & (US$ Million)
Table 98. Middle East and Africa Antianginal Agents Sales by Distribution Channel (2017-2022) & (K Units)
Table 99. Middle East and Africa Antianginal Agents Sales by Distribution Channel (2023-2028) & (K Units)
Table 100. Middle East and Africa Antianginal Agents Revenue by Distribution Channel (2017-2022) & (US$ Million)
Table 101. Middle East and Africa Antianginal Agents Revenue by Distribution Channel (2023-2028) & (US$ Million)
Table 102. Middle East and Africa Antianginal Agents Sales by Country (2017-2022) & (K Units)
Table 103. Middle East and Africa Antianginal Agents Sales by Country (2023-2028) & (K Units)
Table 104. Middle East and Africa Antianginal Agents Revenue by Country (2017-2022) & (US$ Million)
Table 105. Middle East and Africa Antianginal Agents Revenue by Country (2023-2028) & (US$ Million)
Table 106. Teva Corporation Information
Table 107. Teva Description and Major Businesses
Table 108. Teva Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 109. Teva Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 110. Teva Recent Developments
Table 111. Merck Corporation Information
Table 112. Merck Description and Major Businesses
Table 113. Merck Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 114. Merck Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 115. Merck Recent Developments
Table 116. Pfizer Corporation Information
Table 117. Pfizer Description and Major Businesses
Table 118. Pfizer Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 119. Pfizer Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 120. Pfizer Recent Developments
Table 121. Mylan N.V. Corporation Information
Table 122. Mylan N.V. Description and Major Businesses
Table 123. Mylan N.V. Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 124. Mylan N.V. Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 125. Mylan N.V. Recent Developments
Table 126. Elite Pharmaceutical Solution Inc. Corporation Information
Table 127. Elite Pharmaceutical Solution Inc. Description and Major Businesses
Table 128. Elite Pharmaceutical Solution Inc. Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 129. Elite Pharmaceutical Solution Inc. Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 130. Elite Pharmaceutical Solution Inc. Recent Developments
Table 131. Pharmaoffer.com Corporation Information
Table 132. Pharmaoffer.com Description and Major Businesses
Table 133. Pharmaoffer.com Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 134. Pharmaoffer.com Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 135. Pharmaoffer.com Recent Developments
Table 136. AstraZeneca Corporation Information
Table 137. AstraZeneca Description and Major Businesses
Table 138. AstraZeneca Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 139. AstraZeneca Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 140. AstraZeneca Recent Developments
Table 141. ACETO Corporation Information
Table 142. ACETO Description and Major Businesses
Table 143. ACETO Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 144. ACETO Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 145. ACETO Recent Developments
Table 146. Nesher Pharmaceuticals Corporation Information
Table 147. Nesher Pharmaceuticals Description and Major Businesses
Table 148. Nesher Pharmaceuticals Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 149. Nesher Pharmaceuticals Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 150. Nesher Pharmaceuticals Recent Developments
Table 151. Taj pharmaceutical Corporation Information
Table 152. Taj pharmaceutical Description and Major Businesses
Table 153. Taj pharmaceutical Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 154. Taj pharmaceutical Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 155. Taj pharmaceutical Recent Developments
Table 156. Espero BioPharma Corporation Information
Table 157. Espero BioPharma Description and Major Businesses
Table 158. Espero BioPharma Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 159. Espero BioPharma Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 160. Espero BioPharma Recent Developments
Table 161. Hikma Pharmaceuticals Corporation Information
Table 162. Hikma Pharmaceuticals Description and Major Businesses
Table 163. Hikma Pharmaceuticals Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 164. Hikma Pharmaceuticals Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 165. Hikma Pharmaceuticals Recent Developments
Table 166. Athenex Corporation Information
Table 167. Athenex Description and Major Businesses
Table 168. Athenex Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 169. Athenex Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 170. Athenex Recent Developments
Table 171. Aurobindo Pharma Corporation Information
Table 172. Aurobindo Pharma Description and Major Businesses
Table 173. Aurobindo Pharma Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 174. Aurobindo Pharma Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 175. Aurobindo Pharma Recent Developments
Table 176. AMRI Corporation Information
Table 177. AMRI Description and Major Businesses
Table 178. AMRI Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 179. AMRI Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 180. AMRI Recent Developments
Table 181. Intas Pharmaceuticals Corporation Information
Table 182. Intas Pharmaceuticals Description and Major Businesses
Table 183. Intas Pharmaceuticals Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 184. Intas Pharmaceuticals Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 185. Intas Pharmaceuticals Recent Developments
Table 186. Glenmark Pharmaceuticals Corporation Information
Table 187. Glenmark Pharmaceuticals Description and Major Businesses
Table 188. Glenmark Pharmaceuticals Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 189. Glenmark Pharmaceuticals Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 190. Glenmark Pharmaceuticals Recent Developments
Table 191. Troikaa Corporation Information
Table 192. Troikaa Description and Major Businesses
Table 193. Troikaa Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 194. Troikaa Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 195. Troikaa Recent Developments
Table 196. Square Pharmaceuticals Corporation Information
Table 197. Square Pharmaceuticals Description and Major Businesses
Table 198. Square Pharmaceuticals Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 199. Square Pharmaceuticals Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 200. Square Pharmaceuticals Recent Developments
Table 201. Sun Pharmaceutical Corporation Information
Table 202. Sun Pharmaceutical Description and Major Businesses
Table 203. Sun Pharmaceutical Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 204. Sun Pharmaceutical Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 205. Sun Pharmaceutical Recent Developments
Table 206. Unique Pharmaceuticals Corporation Information
Table 207. Unique Pharmaceuticals Description and Major Businesses
Table 208. Unique Pharmaceuticals Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 209. Unique Pharmaceuticals Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 210. Unique Pharmaceuticals Recent Developments
Table 211. Ipca Laboratories Corporation Information
Table 212. Ipca Laboratories Description and Major Businesses
Table 213. Ipca Laboratories Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 214. Ipca Laboratories Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 215. Ipca Laboratories Recent Developments
Table 216. Sandoz Corporation Information
Table 217. Sandoz Description and Major Businesses
Table 218. Sandoz Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 219. Sandoz Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 220. Sandoz Recent Developments
Table 221. Globus Remedies Corporation Information
Table 222. Globus Remedies Description and Major Businesses
Table 223. Globus Remedies Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 224. Globus Remedies Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 225. Globus Remedies Recent Developments
Table 226. Shandong Fangming Pharmaceutical Group Corporation Information
Table 227. Shandong Fangming Pharmaceutical Group Description and Major Businesses
Table 228. Shandong Fangming Pharmaceutical Group Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 229. Shandong Fangming Pharmaceutical Group Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 230. Shandong Fangming Pharmaceutical Group Recent Developments
Table 231. ReYoung Pharmaceutical Corporation Information
Table 232. ReYoung Pharmaceutical Description and Major Businesses
Table 233. ReYoung Pharmaceutical Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 234. ReYoung Pharmaceutical Antianginal Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 235. ReYoung Pharmaceutical Recent Developments
Table 236. Key Raw Materials Lists
Table 237. Raw Materials Key Suppliers Lists
Table 238. Antianginal Agents Distributors List
Table 239. Antianginal Agents Customers List
Table 240. Antianginal Agents Market Trends
Table 241. Antianginal Agents Market Drivers
Table 242. Antianginal Agents Market Challenges
Table 243. Antianginal Agents Market Restraints
Table 244. Research Programs/Design for This Report
Table 245. Key Data Information from Secondary Sources
Table 246. Key Data Information from Primary Sources
List of Figures
Figure 1. Antianginal Agents Product Picture
Figure 3. Global Antianginal Agents Market Share by Type in 2021 & 2028
Figure 3. Nitrates Product Picture
Figure 4. Beta Blockers Product Picture
Figure 5. Calcium Channel Blockers Product Picture
Figure 6. Global Antianginal Agents Market Share by Distribution Channel in 2021 & 2028
Figure 7. Hospital Pharmacies
Figure 8. Retail Pharmacies
Figure 9. Online Pharmacies
Figure 10. Antianginal Agents Report Years Considered
Figure 11. Global Antianginal Agents Sales 2017-2028 (K Units)
Figure 12. Global Antianginal Agents Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Antianginal Agents Revenue 2017-2028 (US$ Million)
Figure 14. Global Antianginal Agents Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 15. Global Antianginal Agents Sales Market Share by Region (2017-2022)
Figure 16. Global Antianginal Agents Sales Market Share by Region (2023-2028)
Figure 17. North America Antianginal Agents Sales YoY (2017-2028) & (K Units)
Figure 18. North America Antianginal Agents Revenue YoY (2017-2028) & (US$ Million)
Figure 19. Europe Antianginal Agents Sales YoY (2017-2028) & (K Units)
Figure 20. Europe Antianginal Agents Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Asia-Pacific Antianginal Agents Sales YoY (2017-2028) & (K Units)
Figure 22. Asia-Pacific Antianginal Agents Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Latin America Antianginal Agents Sales YoY (2017-2028) & (K Units)
Figure 24. Latin America Antianginal Agents Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Middle East & Africa Antianginal Agents Sales YoY (2017-2028) & (K Units)
Figure 26. Middle East & Africa Antianginal Agents Revenue YoY (2017-2028) & (US$ Million)
Figure 27. The Antianginal Agents Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 28. The Top 5 and 10 Largest Manufacturers of Antianginal Agents in the World: Market Share by Antianginal Agents Revenue in 2021
Figure 29. Global Antianginal Agents Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 30. Global Antianginal Agents Sales Market Share by Type (2017-2028)
Figure 31. Global Antianginal Agents Revenue Market Share by Type (2017-2028)
Figure 32. Global Antianginal Agents Sales Market Share by Distribution Channel (2017-2028)
Figure 33. Global Antianginal Agents Revenue Market Share by Distribution Channel (2017-2028)
Figure 34. North America Antianginal Agents Sales Market Share by Type (2017-2028)
Figure 35. North America Antianginal Agents Revenue Market Share by Type (2017-2028)
Figure 36. North America Antianginal Agents Sales Market Share by Distribution Channel (2017-2028)
Figure 37. North America Antianginal Agents Revenue Market Share by Distribution Channel (2017-2028)
Figure 38. North America Antianginal Agents Sales Share by Country (2017-2028)
Figure 39. North America Antianginal Agents Revenue Share by Country (2017-2028)
Figure 40. United States Antianginal Agents Revenue (2017-2028) & (US$ Million)
Figure 41. Canada Antianginal Agents Revenue (2017-2028) & (US$ Million)
Figure 42. Europe Antianginal Agents Sales Market Share by Type (2017-2028)
Figure 43. Europe Antianginal Agents Revenue Market Share by Type (2017-2028)
Figure 44. Europe Antianginal Agents Sales Market Share by Distribution Channel (2017-2028)
Figure 45. Europe Antianginal Agents Revenue Market Share by Distribution Channel (2017-2028)
Figure 46. Europe Antianginal Agents Sales Share by Country (2017-2028)
Figure 47. Europe Antianginal Agents Revenue Share by Country (2017-2028)
Figure 48. Germany Antianginal Agents Revenue (2017-2028) & (US$ Million)
Figure 49. France Antianginal Agents Revenue (2017-2028) & (US$ Million)
Figure 50. U.K. Antianginal Agents Revenue (2017-2028) & (US$ Million)
Figure 51. Italy Antianginal Agents Revenue (2017-2028) & (US$ Million)
Figure 52. Russia Antianginal Agents Revenue (2017-2028) & (US$ Million)
Figure 53. Asia Pacific Antianginal Agents Sales Market Share by Type (2017-2028)
Figure 54. Asia Pacific Antianginal Agents Revenue Market Share by Type (2017-2028)
Figure 55. Asia Pacific Antianginal Agents Sales Market Share by Distribution Channel (2017-2028)
Figure 56. Asia Pacific Antianginal Agents Revenue Market Share by Distribution Channel (2017-2028)
Figure 57. Asia Pacific Antianginal Agents Sales Share by Region (2017-2028)
Figure 58. Asia Pacific Antianginal Agents Revenue Share by Region (2017-2028)
Figure 59. China Antianginal Agents Revenue (2017-2028) & (US$ Million)
Figure 60. Japan Antianginal Agents Revenue (2017-2028) & (US$ Million)
Figure 61. South Korea Antianginal Agents Revenue (2017-2028) & (US$ Million)
Figure 62. India Antianginal Agents Revenue (2017-2028) & (US$ Million)
Figure 63. Australia Antianginal Agents Revenue (2017-2028) & (US$ Million)
Figure 64. China Taiwan Antianginal Agents Revenue (2017-2028) & (US$ Million)
Figure 65. Indonesia Antianginal Agents Revenue (2017-2028) & (US$ Million)
Figure 66. Thailand Antianginal Agents Revenue (2017-2028) & (US$ Million)
Figure 67. Malaysia Antianginal Agents Revenue (2017-2028) & (US$ Million)
Figure 68. Latin America Antianginal Agents Sales Market Share by Type (2017-2028)
Figure 69. Latin America Antianginal Agents Revenue Market Share by Type (2017-2028)
Figure 70. Latin America Antianginal Agents Sales Market Share by Distribution Channel (2017-2028)
Figure 71. Latin America Antianginal Agents Revenue Market Share by Distribution Channel (2017-2028)
Figure 72. Latin America Antianginal Agents Sales Share by Country (2017-2028)
Figure 73. Latin America Antianginal Agents Revenue Share by Country (2017-2028)
Figure 74. Mexico Antianginal Agents Revenue (2017-2028) & (US$ Million)
Figure 75. Brazil Antianginal Agents Revenue (2017-2028) & (US$ Million)
Figure 76. Argentina Antianginal Agents Revenue (2017-2028) & (US$ Million)
Figure 77. Colombia Antianginal Agents Revenue (2017-2028) & (US$ Million)
Figure 78. Middle East and Africa Antianginal Agents Sales Market Share by Type (2017-2028)
Figure 79. Middle East and Africa Antianginal Agents Revenue Market Share by Type (2017-2028)
Figure 80. Middle East and Africa Antianginal Agents Sales Market Share by Distribution Channel (2017-2028)
Figure 81. Middle East and Africa Antianginal Agents Revenue Market Share by Distribution Channel (2017-2028)
Figure 82. Middle East and Africa Antianginal Agents Sales Share by Country (2017-2028)
Figure 83. Middle East and Africa Antianginal Agents Revenue Share by Country (2017-2028)
Figure 84. Turkey Antianginal Agents Revenue (2017-2028) & (US$ Million)
Figure 85. Saudi Arabia Antianginal Agents Revenue (2017-2028) & (US$ Million)
Figure 86. UAE Antianginal Agents Revenue (2017-2028) & (US$ Million)
Figure 87. Antianginal Agents Value Chain
Figure 88. Antianginal Agents Production Process
Figure 89. Channels of Distribution
Figure 90. Distributors Profiles
Figure 91. Bottom-up and Top-down Approaches for This Report
Figure 92. Data Triangulation
Figure 93. Key Executives Interviewed

---